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Original Article

Breast

Direct Hospital Cost of Outcome Pathways in
Implant-Based Reconstruction with Acellular
Dermal Matrices
Ali A. Qureshi, MD*
Kristen Broderick, MD*
Susan Funk, MBA†
Nancy Reaven, MBA†
Marissa M. Tenenbaum, MD*
Terence M. Myckatyn, MD,
FACS, FRCSC*

Background: Current cost data on tissue expansion followed by exchange for
permanent implant (TE/I) reconstruction lack a necessary assessment of the experience of a heterogenous breast cancer patient population and their multiple
outcome pathways. We extend our previous analysis to that of direct hospital cost
as bundling of payments is likely to follow the changing centralization of cancer
care at the hospital level.
Methods: We performed a retrospective analysis (2003–2009) of TE/I reconstructions with or without an acellular dermal matrix (ADM), namely Alloderm RTM.
Postreconstructive events were analyzed and organized into outcome pathways as
previously described. Aggregated and normalized inpatient and outpatient hospital direct costs and physician reimbursement were generated for each outcome
pathway with or without ADM.
Results: Three hundred sixty-seven patients were analyzed. The average 2-year hospital direct cost per TE/I breast reconstruction patient was $11,862 in the +ADM
and $12,319 in the −ADM groups (P > 0.05). Initial reconstructions were costlier in
the +ADM ($6,868) than in the −ADM ($5,615) group, but the average cost of subsequent postreconstructive events within 2 years was significantly lower in +ADM
($5,176) than −ADM ($6,704) patients (P < 0.05). When a complication occurred,
but reconstruction was still completed within 2 years, greater costs were incurred
in the −ADM than in the +ADM group for most scenarios, leading to a net equalization of cost between study groups.
Conclusion: Although direct hospital cost is an important factor for resource and
fund allocation, it should not remain the sole factor when deciding to use ADM
in TE/I reconstruction. (Plast Reconstr Surg Glob Open 2016;4:e831; doi: 10.1097/
GOX.0000000000000848; Published online 9 August 2016.)
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ith a price tag of $7 billion dollars in 2011, breast
reconstruction is under close scrutiny for cost
reduction and value maximization in a healthcare system, experiencing increased pressure to focus on
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bursement strategies to parallel geographic consolidation
of multidisciplinary breast cancer care with bundled payments. Numerous studies have examined the costs associated with autologous breast reconstruction.4,5 However,
the Nationwide Inpatient Sample database shows an absolute and relative increase in the number of breast reconstructions performed with tissue expansion followed
by exchange for a permanent implant (TE/I).6 In fact,
TE/I reconstruction has increased more than 2-fold and
presently accounts for the majority of all reconstructive
breast procedures in the United States, thus highlighting
the need for studying resource allocation and funding of
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this treatment approach.7,8 Paralleling national trends, individual institutions have reported that TE/I reconstructions account for 45% of total cost attributed to breast
reconstruction.7 Despite these changes, there is a paucity
of data to guide how bundling should occur for TE/I. We
have previously reported outcome pathways in TE/I with
acellular dermal matrices and sought to examine the costs
incurred at the hospital level by these outcome pathways.
Practice patterns, including those for TE/I reconstructions evolve as new, innovative technology, are incorporated into practice. Acellular dermal matrices (ADMs)
have caused a paradigm shift in TE/I reconstructions in
the past decade, citing numerous indications, including
but not limited to improved aesthetic outcomes, increased
expansion volumes, and shorter time to final exchange
for permanent implants.9–12 The cost-effectiveness of such
technology has been examined, albeit in a limited fashion, using either retrospective review of previous studies, samples of a larger cohort to extrapolate cost data,
or only index operation costs as cost-minimization, costeffectiveness, and cost-utility analyses.7,13–15 To date, no
study has performed an analysis of ADMs in two-stage implant–based reconstruction using actual cost data directly
incurred by the hospital with representation of the divergent outcome pathways TE/I reconstruction patients undergo. With the advent of accountable care organizations,
bundling of payments and disbursement of funds is likely
to occur at the hospital level. Currently, the hospital typically absorbs the cost of a device like ADM with supply cost
of the item readily apparent to hospital managers. However, the extent to which there are off-setting cost savings
for the hospital over time has not been well studied. It is
imperative for plastic surgeons to be aware of the hospital
costs associated with the services they provide patients in
TE/I reconstruction.
Although cost data should not be the sole factor when
developing a reconstructive plan for a patient, it should be
examined within the context of patient demographics, risk
factors, and their individual treatment algorithms, which
may include chemotherapy and radiation. Current data
about cost of TE/I reconstruction does not fully represent
the experience of a heterogenous patient population and
their multiple outcome pathways. Cost analyses often use
shortened time frames, capturing only costs at or near the
time of reconstruction and missing the full impact of service required to complete a two-staged reconstruction. We
extend our previous analysis to that of cost to set the stage
for meaningful discussions between providers, patients,
and payers to define the value of breast reconstruction.

METHODS
Study Population

A retrospective analysis of all patients treated with
TE/I at Barnes Jewish and Barnes Jewish West County
Hospitals and treated by plastic surgeons from the Washington University School of Medicine from January 1,
2003, to December 31, 2009, was conducted under the
approval of the institutional Human Research Protection
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Office (#201106126) as previously described.16 Immediate and delayed TE/I reconstructions were included for
analysis in patients undergoing unilateral or bilateral skinsparing mastectomies performed for cancer or prophylaxis. All TEs were textured Allergan (Allergan Medical,
Irvine, Calif.) 133MV devices, and implants were Allergan
round moderate- or high-profile silicone or saline devices
(style 15, 20, 68MP, and 68HP) as these were on consignment at our institution during the study period. Patients
with concomitant or previous ipsilateral flap reconstruction, concurrent congenital or acquired ipsilateral breast
deformity, and nipple-sparing mastectomy with immediate
implant and patients for whom flap placement after tissue
expansion was initially planned were excluded. Patients
in which an ADM other than AlloDerm RTM (LifeCell,
Branchburg, N.J.) was used were excluded because usage
of other ADM products, including Alloderm RTU and vicryl mesh, was too infrequent during the study period to
sufficiently power a subset analysis. Medical records were
examined for evidence of postreconstructive events, defined as related procedures or complications. Complications identified included seroma, hematoma, mastectomy
flap necrosis, wound dehiscence with loss of continuity of
the mastectomy incision in the absence of necrosis, cellulitis (infection without seroma), capsular contracture
requiring intervention other than during the expander
exchange, and ADM complications (poor incorporation
or dehiscence of the scaffold). Related procedures included unexpected explantation or capsular revisions and procedures to replace failed devices, manage complications,
or improve symmetry. Explantation was recorded for the
unintended removal of either the TE or permanent breast
implant at any time during the 2-year study period. Capsular revisions were documented when a major revision
of the periprosthetic capsule performed other than at the
implant exchange was used to obtain symmetry or favorable contour. Nipple areolar reconstruction was not evaluated because it was often performed outside the hospital
setting and therefore inconsistently recorded and because
it varied according to patient preference. Common sequences of postreconstructive events were combined into
outcome pathways and analyzed by study arm. Selection
criteria for ADM use were not assessed in this study.
Cost Analyses

Barnes Jewish Hospital provided aggregated cost data
on selected patients, exemplifying patient scenarios or
“cost exemplars.” For the initial reconstruction, privately insured patients with no unrelated procedures were
randomly selected in equal numbers from inpatient and
outpatient settings to represent −ADM and +ADM reconstructions from both earlier and later years of ADM use
at the institution. We excluded cases with a nondominant
brand of tissue expander or unusually long general surgery portion of the case. The mix of bilateral and unilateral reconstructions among cost exemplars was determined
by chi-square to be representative of the entire study arm
for both +ADM (P > 0.05) and −ADM (P > 0.05) reconstructions. In each study arm, a group of 3 representative
patients was identified for each outcome pathway with

Qureshi et al. • Direct Hospital Cost and ADMs
sufficient frequency for analysis. Patients with incomplete
cost data or whose left and right breasts were reconstructed separately were excluded as exemplars.
The hospital supplied aggregated direct cost normalized to 2011 dollars at 3% per annum for postreconstructive events of the cost exemplars in each study arm for
each outcome pathway and for initial reconstructions.
“Direct costs” are those that can be traced directly to a department, product, or service, excluding overhead costs,
and thus reflect the hospital’s assessment of the cost it incurred, providing the specific services and supplies used
by the patients.17 The average per-patient cost obtained
for each group of exemplars was applied to all patients in
the same outcome pathway and study arm. Billing operations from the Washington University Physicians medical
group provided aggregated data on physician reimbursement for these “cost exemplars” on the same basis.
Statistical Analyses

The overall cost data between patients who had ADM
and those who did not was amenable to statistical comparison with a two-sample independent t test because there
was no variance in the averaged costs assigned to patients
in each reconstructive pathway. Statistical analyses were
performed using SAS/STAT version 9.2 (SAS Corporation, Cary, N.C.). Statistically significant findings were
reported when P < 0.05. Hospital requirements preclude
disclosure of patient-level cost data because of its proprietary nature. Because we could not perform patient-level
analyses, we averaged costs for patients exemplifying a particular pathway. Because all patients in a pathway are assigned the same cost, based on the pathway average, there
is no variance between patients. As such, cost differences
between the 2 study arms for the same pathway or for the
initial reconstruction cannot be evaluated statistically.

RESULTS

Three hundred sixty-seven of 415 patients had sufficient information for inclusion in the cost analyses
(+ADM = 265; −ADM = 102), and their demographic information is summarized in Table 1. The average age of
patients was 50 (+ADM = 50; −ADM = 50), and body mass
index (BMI) was 28.2 kg/m2 (+ADM = 27.7; −ADM = 29.4).
The total average 2-year hospital direct cost per TE/I
breast reconstruction patient was $11,862 in the +ADM
and $12,319 in the −ADM groups (Fig. 1A). Initial reconstructions were costlier in the +ADM ($6,868) than the
−ADM ($5,615) group, but the average cost of subsequent
postreconstructive events within 2 years was significantly
lower in +ADM ($5,176) than –ADM ($6,704) patients
Table 1. Cost Study Patient Population Demographics
+ADM
No. of patients
Age (y), mean (SD)
BMI, kg/m2, mean (SD)
Bilateral, n (%)
Radiation, n (%)
Smoker, n (%)
BMI, body mass index.

265
50 (9.8)
28 (6.6)
126 (48)
64 (24)
36 (14)

−ADM
102
50 (9.3)
30 (8.2)
45 (44)
36 (35)
16 (16)

(P < 0.05) (Table 2). Uneventful implant exchange cost
an additional $2,974 in the +ADM and $4,036 in the
–ADM groups, whereas the need for additional revisions
further escalated cost (Table 2). Of note, only 1 patient
in the +ADM group and none in the –ADM group experienced capsular contracture requiring surgery not concurrent with the expander exchange.
In cases where a complication occurred, but reconstruction was still completed within 2 years, costs incurred
were greater in the –ADM than in +ADM group for most
scenarios (Table 2 and Fig. 1A). Rates of cellulitis without
seroma requiring explant with eventual implant exchange
within 2 years (Table 2, pathway III) occurred in 4% of
+ADM ($7,414) and 5% of –ADM ($11,298) reconstructions. Rates of seroma (Table 2, pathway IV) were also similar in both groups (4% vs 3%) but cost more for +ADM
($11,586) than −ADM ($8,139) reconstructions. Dehiscence without necrosis (Table 2, pathway V) was more
common in −ADM versus +ADM reconstructions (12% vs
4%) with an additional cost of $12,009 and $14,200, respectively. Necrosis without dehiscence (Table 2, pathway
VI) occurred more commonly with ADM reconstruction
(6% vs 2%) but cost less on average per patient ($6,398 vs
$8,762). Rates of conversion to autologous reconstruction
(Table 2, pathway VII) were similar in both groups and
cost $14,434 and $19,169 for +ADM and −ADM groups.
Cellulitis eventually leading to explantation with an abandoned reconstruction at 2 years (Table 2, pathway VIII)
was less costly in the +ADM group ($2,224 vs $5,004).
Reconstruction that was incomplete or abandoned after
complications (Table 2, pathway IX) were similar (7%
and 5%) with costs of $3,758 and $2,648 in the +ADM and
−ADM groups.
Surgeon charges and reimbursements with ADM for
inpatient services were $5,900 and $3,887 and for outpatient services $5,103 and $3,849, respectively (Fig. 1B).
Without ADM, surgeon charges and reimbursements for
inpatient services were $7,116 and $3,028 and for outpatient services $3,559 and $3,144, respectively. Charges and
reimbursements were not significantly different regardless
of ADM use or inpatient versus outpatient setting of services rendered.
The average surgeon charges per patient for postreconstruction services was $10,112 with ADM and $12,476
without ADM. Average surgeon reimbursement per patient for postreconstruction services was $4,067 with ADM
and $4,887 without ADM. Physician charges and reimbursements were similar between study arms (Fig. 1C).

DISCUSSION

With the advent of bundled payments and geographic
consolidation of cancer care around hospitals and cancer
centers,18,19 it remains imperative for plastic surgeons to be
informed about the costs at the hospital level for patients
who undergo TE/I reconstruction, as this is the most
commonly performed reconstruction and is increasing
in popularity.6 Previous studies have compared the costs
of TE/I reconstruction versus autologous reconstruction,
but the TE/I reconstructions examined did not include
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Fig. 1. Two-year hospital direct costs, surgeon charges, and reimbursement for staged TE/I reconstructions. Data are reported as perpatient average. A, Hospital direct costs, including initial TE operation ±ADM and 2 y post TE reconstructive events. B, Surgeon charges
and reimbursements for initial TE/I reconstruction ±ADM in inpatient versus outpatient settings. C, Surgeon charges and reimbursements
for 2 y after initial TE reconstruction ±ADM. IP, inpatient setting; OP, outpatient setting.

reconstructions with ADM.5,8 Other studies examining the
cost of ADM use have studied the costs incurred based on
individual complication events and not in the setting of a
longitudinal experience or outcome pathways as we have
previously described.13–16 The present study is important
because very little has been published previously about
cost from a hospital’s perspective as these data are difficult to obtain, yet it is the hospital that absorbs the cost of
the ADM. Although the cost of ADM or any surgical device may be obvious to the hospital, no hospital administration’s budget has a line item that would show offsetting
cost reductions over time. We think that the perspective
offered by this study is not only novel but also particularly
informative to discussions on value in breast reconstruction.
At our institution, the use of ADM in TE/I reconstruction increased substantially after its introduction in 2005,
was limited to sheets that were 12 × 6, 16 × 6, or 16 × 8 cm2

and parallels other single-institution experiences with
ADM.7,15 One of the main criticisms of using any ADM is its
product cost. In our series, the initial direct hospital cost
of TE/I reconstruction was higher when ADM was used,
but the difference was lower than the list price for even the
smallest sheet of ADM used in this series (6 × 12 cm).13,20
One variable that may influence this cost discrepancy is
lower negotiated ADM product costs at the institutional
level. Our analysis, however, highlights an important fact
about not only the present study but also cost analysis as a
whole: the cost of an ADM may not be accurately reflected
by simply inputting its retail cost into a hypothetical model
as its utilization may impact operative time, surgical technique, negotiated product costs with the vendor, among
other factors that influence direct hospital cost.
Cost also needs to be evaluated in the context of patient’s outcome pathways. We found that the weighted,
average hospital direct cost of reconstructive events in

Table 2. Hospital Direct Cost per Patient for Postreconstructive Services Within 2 y by Outcome Pathway
+ADM

−ADM

Average Hospital Direct per Patient
Cost (2011 $)
Initial TE reconstruction
Outcome pathway after initial TE reconstruction
 I. Uneventful two-stage expander reconstruction within 2 y
 II. Successful two-stage expander reconstruction with additional services
  IIa. + extra procedure for symmetry
  IIb. + extra procedure for other reasons
  IIc. + ADM complication
  IId. + extra capsule revision for capsular contracture
 III. Cellulitis without seroma, eventual explant, and stage 2 completed
 IV. Seroma, stage II completed
 V. Dehiscence with or without necrosis, no seroma, stage 2 completed
 VI. Necrosis without dehiscence, no seroma, stage 2 completed
 VII. Converted to autologous reconstruction
 VIII. Cellulitis, eventual explant, reconstruction abandoned
 IX. Reconstruction incomplete or abandoned after complications
(seroma, necrosis, and dehiscence)
Postreconstructive events within 2 y
Grand total: initial reconstruction + postreconstructive events

4

P

$6,686
$5,615
Average hospital direct cost per patient for
postreconstructive services, in 2011 $
$2,974

$4,036

$4,792
$8,838
$5,755
$8,003
$7,414
$11,586
$14,200
$6,398
$14,434
$2,224
$3,758

$6,112
$7,454
$11,298
$8,139
$12,009
$8,762
$19,169
$5,004
$2,648

$5,176
$11,862

$6,704
$12,319

0.0003
0.2788
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the 2 years after TE insertion varied by clinical pathway,
but overall it was significantly lower in patients who had
ADM. The net effect was an equalization of overall cost
between study arms inclusive of the initial TE procedure
and any procedures up until exchange with an implant or
autologous flap within the 2-year period of the study. Importantly, although the majority of 2-year reconstructive
pathways were less costly in the +ADM study arm, these
differences must be interpreted with caution as pathwaylevel statistical comparisons could not be performed for
reasons outlined in the Methods section.
The 2-year costs of successful reconstructions that
require no or only minor revisions or unsuccessful reconstructions that were abandoned were considerably
cheaper than those requiring interventions for salvage.
BMI, radiation, and smoking influenced postreconstructive events and the outcome pathways that they associate
with to a greater extent than whether ADM was used as
we have previously reported.16 Hence, the decision to use
ADM or not needs to be based on patient-specific factors,
including but not limited to BMI and radiation and not
solely on cost.
We found that the percent of patients who were irradiated differed significantly between the study arms (±ADM,
P < 0.05). Our previous study found that irradiated patients
were 2.2 times more likely than patients without radiation
to have complications or additional procedures, veering
away from an uneventful reconstruction.16 Subset analysis of ADM patients who were irradiated showed average
downstream costs of $6,422 versus $4,704 for those without radiation. If 35% of the ADM study arm had incurred
$1,719 in additional costs (i.e., 92 instead of 64 irradiated
patients), we estimate this would had added $181.59 to
total cost per ADM patient. This modest increase in cost
(1.5%) is not enough to change our overall finding that
over 2 years, average cost per patient reconstructed with
ADM trended lower albeit not significantly than patients
without ADM. Our findings add to previous reports of
TE/I reconstruction without ADM in which pre- or postoperative radiation did not significantly affect costs.8
Our analysis included surgeon charges and reimbursements for initial TE/I reconstruction ±ADM in inpatient
versus outpatient settings and also surgeon charges and
reimbursements for 2 years after initial TE reconstruction
±ADM. These were not found to be significantly different,
suggesting that physician provider cost does not vary with
the use of ADM at our institution. Although charges and
reimbursements are measures of revenue rather than physician cost, the findings suggest that revenue incentives
for physicians are not misaligned with cost incentive for
hospitals, as often can happen. From the perspectives we
analyzed, over a 2-year time period, neither hospitals nor
physicians have a significant financial incentive to use or
avoid the use of ADM.
Our study has several limitations. Analysis was based
on “direct costs” or the cost that can be traced directly
to a department, product, or service, excluding overhead
costs.17 We felt that the hospital’s assessment of the cost it
incurred providing the specific services and supplies used
by the patients would be valuable information with the

advent of systems, such as accountable care organizations
and reimbursement based on hospital billing. In addition,
although our assessment of direct cost is at 2 hospitals, it
still represents the experience of 1 hospital system but lays
the foundation for studies in other institutions in other
geographic locations. In our study, costs were aggregated
from a limited group of patients, and line item and patient-level cost detail were unavailable.
Trends in TE/I reconstruction are rapidly evolving
with increased use of fat grafting as a subsequent procedure.20 Further investigation on the costs incurred by
these procedures will need to be examined as fat grafting is becoming a near routine “touch up” procedure for
breast revisions in TE/I reconstructions at many institutions, including our own.
Because there is an equalization of overall direct hospital cost between the 2 study groups, our findings point
to ADM use as 1 factor in a complex web of interactions
that impact costs. Its limited impact on cost over a 2-year
period suggests that the more important focus might be
on careful attention to risk and patient factors associated
with different TE/I reconstruction outcome pathways.
Terence M. Myckatyn, MD, FACS, FRCSC
Division of Plastic and Reconstructive Surgery
Washington University School of Medicine
1020 N. Mason Rd, Ste 110,
St. Louis, MO 63141
E-mail: myckatyn@wudosis.wustl.edu
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